Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
The DOI matches its Crossref record; 111 of the 112 references it cites were found in a registry or an index.
Abstract
Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are intrinsically linked: obesity increases the risk of diabetes and also contributes to disease progression and cardiovascular disease. Although the benefits of weight loss in the prevention of diabetes and as a critical component of managing the condition are well established, weight reduction remains challenging for individuals with type 2 diabetes due to a host of metabolic and psychological factors. For many patients, lifestyle intervention is not enough to achieve weight loss, and alternative options, such as pharmacotherapy, need to be considered. However, many traditional glucose-lowering medications may lead to weight gain. This article focuses on the potential of currently available pharmacological strategies and on emerging approaches in development to support the glycemic and weight-loss goals of individuals with type 2 diabetes. Two pharmacotherapy types are considered: those developed primarily for blood glucose control that have a favorable effect on body weight and those developed primarily to induce weight loss that have a favorable effect on blood glucose control. Finally, the potential of combination therapies for the management of obese patients with type 2 diabetes is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“Weight reduction, therefore, is a key therapeutic goal in both the prevention and management of type 2 diabetes (5).”
BackgroundMechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · cited 1×
“Obesitydin particular abdominal obesitydis a major driver in the development of diabetes and cardiovascular disease (2), with the increasing prevalence of obesity mirrored by the rising prevalence of diabetes (3).”
BackgroundXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 1×
“Orlistat was generally well tolerated, and gastrointestinal effects were the most commonly reported AEs, but all events were considered mild or moderate (75,76).”
BackgroundYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Research works printed but not linked: 1
- Ferrannini, 2014, Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition, Diabetologia, 57, S8
Cited by
Items 101–200 of 221
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
Liu, Y., & Luo, X. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0873-2 · Cited by 15
“Moreover, complex medication regimens [15,16], subsequent adverse events, medication-induced weight gain, and possible risk of hypoglycemia [29] may affect patient compliance and further hinder the achievement of blood-glucose goals.”
BackgroundAbdulrasheed-Adeleke, T., Lawal, B., Agwupuye, E. I., Kuo, Y., Eni, A. M., Ekoh, O. F., Lukman, H. Y., Onikanni, S. A., Olawale, F., Sani, S., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114582 · Cited by 12
Kabir, A., Mousavi, S. E., & Pazouki, A. (2018) · Current Diabetes Reviews · doi:10.2174/1573399814666180403164529 · Cited by 13
Li, X., van Giessen, A., Altunkaya, J., Slieker, R. C., Beulens, J. W. J., Hart, L. M. ‘., Pearson, E. R., Elders, P. J. M., Feenstra, T., & Leal, J. (2023) · Diabetes Care · doi:10.2337/dc22-2170 · Cited by 12
Kwan, S. H., & de Mejía, E. G. (2024) · Nutrients · doi:10.3390/nu16020329 · Cited by 13
“Another animal study demonstrated the capacity of cooked adzuki beans to improve weight after short treatment [10].”
BackgroundPlant proteins and peptides as key contributors to good health: A focus on pulses
Luzardo‐Ocampo, I., & de Mejía, E. G. (2025) · Food Research International · doi:10.1016/j.foodres.2025.116346 · Cited by 15
The impact of Ramadan fasting on Fetuin-A level in type 2 diabetes mellitus
Harbuwono, D. S., Sazli, B. I., Kurniawan, F., Darmowidjojo, B., Koesnoe, S., & Tahapary, D. L. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06773 · Cited by 12
“The decrease in body weight could lead to normalization of BMI in obese T2DM patients and potentially affect glycemic control positively, which is one of the targets that should be achieved by DM patients [30].”
BackgroundBoye, K. S. (2021) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2021.15.555904 · Cited by 13
A Composition of Phytonutrients for Glycemic and Weight Management
Urasaki, Y., & Le, T. T. (2022) · Nutrients · doi:10.3390/nu14183784 · Cited by 11
“In contrast, managing Type 2 diabetes involves glycemic and weight management [7].”
BackgroundPang, S., Man, Q., Song, S., Song, P., Liu, Z., Li, Y., Jia, S., Wang, J.-Z., Zhao, W., & Zhang, J. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1682959 · Cited by 13
Functional Complementation of Anti-Adipogenic Phytonutrients for Obesity Prevention and Management
Urasaki, Y., & Le, T. T. (2022) · Nutrients · doi:10.3390/nu14204325 · Cited by 11
“Weight loss via caloric restriction and exercise is clearly the most effective strategy for the prevention of obesity and associated diseases [4].”
BackgroundWoo, V. C., Bell, A., CLEMENT, M. A., Noronha, L., Tsoukas, M. A., Camacho, F., Traina, S., Georgijev, N., Culham, M. D., Rose, J. B., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13573 · Cited by 10
Glucoregulatory Properties of Fermented Soybean Products
Yu, S., Wang, W., Li, S., Li, J., Zhao, R., Liu, D., & Wu, J. (2023) · Fermentation · doi:10.3390/fermentation9030254 · Cited by 10
Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
Basile, L., Cannarella, R., Iuliano, S., Calogero, A. E., Condorelli, R. A., Greco, E. A., Aversa, A., & Vignera, S. L. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04103-9 · Cited by 11
Padhiyar, P. N., Singh, B. P., Sarkar, P., & Hati, S. (2025) · Sustainable Food Proteins · doi:10.1002/sfp2.70012 · Cited by 13
“Diabetic care involves a multifaceted strategy to lower sugar levels and promote insulin tolerance, including obesity, nutrition, and therapy (Van Gaal and Scheen 2015).”
Secondary prevention of cardiovascular disease: Unmet medical need, implementation and innovation
Grobbee, D. E., & Pellicia, A. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317709369 · Cited by 9
“However, sustained weight loss is difficult to achieve.(13) Overall, obesity rates in Europe, as in many other parts of the world, show steady increases, heralding an epidemic of cardiovascular disease that risks negating the progress made in disease prevention and treatment over the last decades.”
BackgroundBenchmarks of Diabetes Care in Men Living With Treated HIV-Infection: A Tertiary Center Experience
Fazekas, M., Tonks, K. T. T., & Samaras, K. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00634 · Cited by 11
“Pharmacotherapies that can also assist in both weight management include metformin and the glucagon peptide-1 agonists exenatide and liraglutide (43).”
BackgroundWu, T., Wong, C. K. H., Lui, D. T. W., Wong, S. K., Lam, C. L. K., Chung, M. S. H., McAllister, D., Welbourn, R., & Dixon, J. B. (2023) · BJS Open · doi:10.1093/bjsopen/zrad077 · Cited by 12
Rizos, C. V., Filippatos, T. D., & Elisaf, M. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1418325 · Cited by 10
Füchtenbusch, M., Aberle, J., Heitmann, E., Nicolay, C., & Jung, H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13658 · Cited by 11
Obesity Education Strategies for Cancer Prevention in Women’s Health
Liu, L., Segura, A., & Hagemann, A. R. (2015) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-015-0129-8 · Cited by 9
Jain, P., Hejjaji, V., Thomas, M. B., Garcia, R. A., Kennedy, K. F., Goyal, A., Sperling, L., Das, S. R., Hafida, S., Enriquez, J. R., et al. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01217-w · Cited by 8
Gulati, K., Wijndaele, K., Webb, J., von Arx, L., Seif, M., Jennison, T., Geneidat, A., Wild, R., Wood, R. P., & Khunti, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16201 · Cited by 9
A time to revisit the two oldest prandial anti-diabetes agents: acarbose and repaglinide
Pishdad, P., Pishdad, R., Pishdad, G. R., & Panahi, Y. (2020) · Endocrine · doi:10.1007/s12020-020-02396-0 · Cited by 8
Karkare, S. U., Fridman, M., Dang‐Tan, T., Lu, J., Smolarz, B. G., DeKoven, M., & Iyer, N. N. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.18321 · Cited by 10
Effects of Pharmaceutical Substances with Obesogenic Activity on Male Reproductive Health
Mascarenhas, C., Sousa, A. C. A., & Rato, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042324 · Cited by 11
“Thus, the anabolic characteristics of insulin can cause weight gain by inhibiting lipolysis and proteolysis [26,27].”
BackgroundBoutari, C., Pοlyzos, S. A., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.03.007 · Cited by 8
Yamauchi, T., Asakura, T., Shingaki, T., Oura, T., & Katagiri, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16500 · Cited by 10
Setiono, F., Jock, B., Trude, A. C. B., Wensel, C. R., Poirier, L., Pardilla, M., & Gittelsohn, J. (2019) · Current Developments in Nutrition · doi:10.1093/cdn/nzz067 · Cited by 14
Caturano, A., Nilo, D., Lorenzo, G. D., Rocco, M. P., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Moretto, S. M., Acierno, C., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm43143 · Cited by 9
“%) lead to consistent improvements in steatosis, while greater losses may reverse fibrosis [146– 148].”
Coleman, C. D., Kiel, J., Mitola, A. H., & Arterburn, L. M. (2017) · Nutrition and Diabetes · doi:10.1038/nutd.2017.32 · Cited by 8
Koopman, A. D. M., Ven, M. V., Beulens, J. W. J., Welschen, L. M. C., Elders, P. J. M., Nijpels, G., & Rutters, F. (2018) · Journal of Diabetes Research · doi:10.1155/2018/9264204 · Cited by 9
Chaker, F., Kallel, A., Khessairi, N., Yazidi, M., Oueslati, I., Chatti, H. A., Feki, M., & Chihaoui, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1536402 · Cited by 9
Meißner, N., Ramos‐Pascual, S., Ortwig, K. A., van Rooij, F., Schrednitzki, D., Stöve, J., & Halder, A. M. (2026) · Journal of Experimental Orthopaedics · doi:10.1002/jeo2.70651 · Cited by 7
“For instance, patients with diabetes often remain diabetic despite weight reduction [6, 79].”
Kaku, K., Naito, Y., Senda, M., Kurihara, Y., Gunji, R., Kakiuchi, S., & Utsunomiya, K. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13125 · Cited by 4
Tshiswaka, D. I., Agala, C. B., Guillory, A., Walters, B., & Mbizo, J. (2020) · BMC Public Health · doi:10.1186/s12889-020-09231-1 · Cited by 5
Hong, M. K., Cho, Y. Y., Rha, M., Kim, J. H., & Lee, M. (2015) · Clinical Nutrition Research · doi:10.7762/cnr.2015.4.3.201 · Cited by 6
“The benefits of weight loss in the prevention and management of diabetes have been reported in a number of studies, and a 5% weight loss was reported to improve FBG levels and reduce the need for diabetes medications [13-16].”
BackgroundStatus of Diabetes Care: New Challenges, New Concepts, New Measures—Focusing on the Future!
Cefalu, W. T., Boulton, A. J. M., Tamborlane, W. V., Moses, R. G., LeRoith, D., Greene, E. L., Hu, F. B., Bakris, G. L., Wylie‐Rosett, J., Rosenstock, J., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0875 · Cited by 5
Geerling, R. H., Anglim, J., Kothe, E. J., Schram, M. T., Holmes‐Truscott, E., & Speight, J. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292553 · Cited by 10
Matza, L. S., Stewart, K. D., Redig, J., Howell, T. A., Morris, W., Newson, R. S., Yasui, A., Ishak, J., & Boye, K. S. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2316400 · Cited by 4
“Consequently, there has been growing interest in medications for diabetes that also promote weight reduction 5,6 .”
Farmanbar, R., Zeidi, I. M., & Afkar, A. (2018) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.64581 · Cited by 4
Zang, L., Yin, H., Chen, L., Da-qing, H., Jin, H., Yang, N., Shi, X., Liang, L., Liu, M., Fan, H. S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0645-z · Cited by 7
Hejjaji, V., Martínez, J. J. G., Tang, F., Garnelo, J. B., Cooper, A., Medina, J., Mutiozabal, M. S., Khunti, K., Nicolucci, A., Shestakova, M. V., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14745 · Cited by 4
“weight, prior reports have demonstrated that it can be very hard to achieve and even harder to sustain, with over half of those who lost weight regaining it over 8 years.(11) Furthermore, the selection of GLMs can be particularly helpful or harmful to participants with type 2 diabetes in their efforts to lose weight.”
BackgroundSingh, R. P., Goswami, S., & Pathak, S. (2023) · Annals of Phytomedicine An International Journal · doi:10.54085/ap.2023.12.2.66 · Cited by 4
Moher, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35868-2.00033-5 · Cited by 6
Whitley, H. P., Smith, W. D., Hanson, C., & Parton, J. (2020) · Patient Education and Counseling · doi:10.1016/j.pec.2020.05.015 · Cited by 5
Exciting breakthroughs in the management of diabetes mellitus
Scheen, A. J. (2021) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2021.100005 · Cited by 7
Self-citationDrawbacks of Olanzapine Therapy: An Emphasis on Its Metabolic Effects and Discontinuation
Oruch, R., Rajab, H. A., Elderbi, M., Pryme, I. F., Fasmer, O. B., & Lund, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228125 · Cited by 7
Murfet, G. O., Robertson, I. K., Luccisano, S. P., & Kilpatrick, M. (2024) · Clinical Obesity · doi:10.1111/cob.12715 · Cited by 5
“10,13 15 However, people in rural/remote areas often experience reduced access to health services, including allied health, and limited nutritious dietary and physical activity options and environments.”
Karmankar, S. R., & Tajne, M. R. (2019) · Asian Journal of Chemistry · doi:10.14233/ajchem.2019.21824 · Cited by 3
Comer-HaGans, D., Austin, S., Ramamonjiarivelo, Z. H., & Sherman, L. D. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.11.020 · Cited by 5
What's new in nutrition for adults with diabetes?
Nwankwo, R. B., & Funnell, M. M. (2016) · Nursing · doi:10.1097/01.nurse.0000480595.99521.56 · Cited by 3
Preventive and Therapeutic Effects of Dietary Fibers Against Cardiovascular Diseases
Raman, M., Ambalam, P. S., & Doble, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811442-1.00012-2 · Cited by 3
Inhibiteur de la DPP-4 ou des SGLT2 après échec de la metformine seule dans le diabète de type 2
Paquot, N., & Scheen, A. J. (2017) · JMIG · doi:10.53738/revmed.2017.13.571.1410 · Cited by 5
Self-citationXu, L., Yu, S. Q., Gao, L., Huang, Y., Wu, S., Yang, J., Sun, Y. X., Yang, Z., Chai, S. B., Zhang, Y., et al. (2020) · PubMed · doi:10.3967/bes2020.005 · Cited by 3
2024 Thai guidelines on the treatment of hypertension
Kunanon, S., Kotruchin, P., Chattranukulchai, P., Chotruangnapa, C., Roubsanthisuk, W., Vathesatogkit, P., Kunavisarut, T., Silaruks, S., Tejavanija, S., Wataganara, T., et al. (2025) · Asian Biomedicine · doi:10.2478/abm-2025-0034 · Cited by 3
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Aberle, J., Forst, T. M., Heitmann, E., Görgens, S. W., & Seufert, J. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2078-9491 · Cited by 4
“Dabei zeigen Studien, dass sich bereits eine Senkung des glykierten Hämoglobins (HbA1c) um 1% auf viele diabetesbedingte Komplikationen positiv auswirkt, während eine 5–10 %ige Gewichtsreduktion sowohl den HbA1c-Wert als auch kardiovaskuläre Risikofaktoren verbessert [9, 10, 11, 12].”
BackgroundTratamiento de la diabetes mellitus (I)
Alcántara, V., & Pérez, A. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.010 · Cited by 11
GLP-1 Receptor Agonists for the Treatment of Diabetes and Obesity
Palani, A., Zhou, Y., Halleck, M. M., & Carrington, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13765-5 · Cited by 2
Effects of Namya Kanom Jeen powder extracts on anti-oxidative and anti-inflammatory properties
Dat-arun, P., Leelawattana, R., & Chinachoti, P. (2018) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v8i8.383 · Cited by 2
Obesity: Genetics, Pathogenesis, Therapy
Mathew, H., Paschou, S. Α., Aramapatzi, K. M., Hsu, W. C., & Mantzoros, C. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_30-2 · Cited by 2
Treatment Goals in Diabetic Nephropathy
Vervoort, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_25 · Cited by 2
Médicaments anti-obésité : leçons des échecs pour l’avenir
Scheen, A. J. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.10.012 · Cited by 4
Self-citationGlenn, A. J., & Liu, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1094954 · Cited by 4
Future Drug Treatments for Type 2 Diabetes
Bailey, C. J. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch79 · Cited by 2
Wal, A., Sahu, P. K., Wal, P., Sahu, K., Bhise, M. R., & Lodhi, D. S. (2025) · Cardiovascular & Hematological Disorders-Drug Targets · doi:10.2174/011871529x326042241031060350 · Cited by 1
Cooper, M., Nørregaard, P. K., Andersson, G. N., Linget, J., Högberg, T., Little, P. B., Receveur, J., & Elling, C. E. N. (2025) · Journal of Molecular and Clinical Medicine · doi:10.31083/jmcm36687 · Cited by 1
Thiyagarajan, S. K., Wall‐Wieler, E., Liu, Y., Zheng, F., & Edwards, M. (2026) · Obesity Surgery · doi:10.1007/s11695-025-08467-3 · Cited by 2
“Obesity has a strong association with T2D [2, 3] Among individuals with both conditions, weight management and glycemic control are essential to reducing long-term morbidity.”
Review of the Pharmacological and Bariatric Surgery for Diabesity
Eligar, V. S., & de Gruchy, E. (2017) · MOJ Drug Design Development & Therapy · doi:10.15406/mojddt.2017.01.00005 · Cited by 1
“…combination Phentermine Targets hypothalamus to Stimulate adrenal glands to release noradrenaline which regulates appetite and promotes satiety (Van Gaal & Scheen, 2015) Insomnia, irritability (Yanovski & Yanovski, 2014) 9% weight loss (Yanovski & Yanovski, 2014) 67-70% (Yanovski & Yanovski,…”
BackgroundInfluentialTraina, S., Slee, A. E., Sanden, S. V., & Diels, J. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0343-7 · Cited by 1
“While glycemic control is the fundamental goal in the treatment of T2DM, adherence to behaviors that promote glycemic control may be critically undermined by a lack of simultaneous weight management [9].”
BackgroundPerspectives dans le traitement pharmacologique du diabète de type 2 pour les 10 prochaines années
Scheen, A. J. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30043-9 · Cited by 2
Self-citationSauchelli, S., Bradley, J., Cox, J. S., England, C. Y., & Perry, R. E. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01467-7 · Cited by 1
Ahn, E., Shin, S., Choi, S., & Kim, E. (2023) · Journal of Nutrition and Health · doi:10.4163/jnh.2023.56.1.24 · Cited by 1
Obesity and Diabetes: Clinical Aspects
Wharton, S., Christensen, R. A. G., Costanian, C., Gershon, T., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_41 · Cited by 1
How to apply the Canadian Obesity Clinical Practice Guidelines to people with type 2 diabetes
Pedersen, S. D. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.115 · Cited by 1
Deshpande, S. V., Deshpande, V., Kohli, K. R., Tamoli, S., & Sakapal, S. S. (2023) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2023.100768 · Cited by 1
Role of Phytoconstituents of Medicinal Plants in Curing Type 2 Diabetes
(2024) · Journal of Food Chemistry and Nanotechnology · doi:10.17756/jfcn.2024-s1-005 · Cited by 2
“Despite having evident pathophysiological crosstalk be-tween diabetes and obesity, the choices of drugs suitable for the combined treatment of diabetes and obesity are limited in modern medicine [47].”
BackgroundAhmed, V. A., Rahman, H. S., Raheem, M. O. M., Othman, H. H., Algarawi, M., & Ibnaouf, K. H. (2024) · Natural Product Communications · doi:10.1177/1934578x241259377 · Cited by 1
Obesity: New paradigms, interventions and treatments
Cook, D. (2017) · Nurse Prescribing · doi:10.12968/npre.2017.15.7.338 · Cited by 1
What's New in Nutrition for Adults With Diabetes?
Nwankwo, R. B., & Funnell, M. M. (2017) · Home Healthcare Now · doi:10.1097/nhh.0000000000000576 · Cited by 2
Dat-arun, P., Leelawattana, R., & Chinachoti, P. (2018) · Bioactive Compounds in Health and Disease · doi:10.31989/bchd.v1i8.549 · Cited by 3
Huynh, J., Menezes, H. T., Gerstein, H. C., & Sherifali, D. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.06.004 · Cited by 1
Diabetic nephropathy: Pathophysiology, Staging, Prevalence, and Management
Karale, S., Johnson, J. A., Joseph, M. E., Abraham, J., & Shahadan, S. (2020) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2020.015 · Cited by 1
Obesity: Genetics, Pathogenesis, Therapy
Paschou, S. Α., Mathew, H., & Mantzoros, C. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-20797-1_30-1 · Cited by 1
A new angle for glp-1 receptor agonist: the medical economics argument
Valencia, W. M., & Florez, H. J. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1069297 · Cited by 1
Bailey, C. J., & Krentz, A. J. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch35 · Cited by 2
Raubenheimer, J., Myburgh, P. H., & BHAGAVATH, A. S. (2024) · Research Square · doi:10.21203/rs.3.rs-4284610/v1 · Cited by 1
MIR192 Upregulates GLP-1 Receptor and Improves Statin-Induced Impairment of Insulin SecretionPreprint
Kuang, Y., Locatelli, C. A. A., Qin, Y., Zhang, Y., Theusch, E., Muñoz, A. S., Sánchez, G., Lü, M., Nguyen, M.-A., Yalamanchili, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.18.643960 · Cited by 1
“Importantly, GLP1R agonists have been shown to not only reduce blood glucose, but also to reduce obesity 47 and to protect against atherosclerotic cardiovascular disease 48 , the leading cause of death in patients with T2DM 49 .”
Cortes-Oliveira, C. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2016.tde-06012016-153552
Al-Tabakha, M. M., Obaid, D. E. E., Fahelelbom, K. M., & Sadek, B. S. (2016) · Journal of Young Pharmacists · doi:10.5530/jyp.2016.4.23
What's new in nutrition for adults with diabetes?
Nwankwo, R. B., & Funnell, M. M. (2016) · Nursing Management · doi:10.1097/01.numa.0000491124.22612.0e
¿Cuáles son las novedades en nutrición para adultos con diabetes?
Nwankwo, R. B., & Funnell, M. M. (2016) · Nursing (Ed española) · doi:10.1016/j.nursi.2016.11.008
Resolving the KgA1c paradox in the management of type 2 diabetes mellitus
Davidson, J. A., Kalra, S., Singh, V., Fegade, M., Singh, G., & Mane, A. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.12.026
“accentuates the detrimental effects of T2DM.[26]”
Is Type 2 Diabetes a Surgical Disease?
Yeung, K. T. D., & Ahmed, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-93545-4_37
Wharton, S., Costanian, C., Gershon, T., & Christensen, R. A. G. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_39 · Cited by 2
Suhartatik, M., & Sartika, R. A. D. (2019) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2020.v13i1.35981
Bark, S.-W., & Kim, H. (2020) · Journal of Environmental Science International · doi:10.5322/jesi.2020.29.4.351
Laugesen, C., Ranjan, A. G., Schmidt, S., Rasmussen, L. N., Nørgaard, O., Christensen, R., & Nørgaard, K. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038970
Oral Health Care Guidelines for Patients with Diabetes Mellitus: A Review
Rao, P. K. (2020) · Indian Journal of Forensic Medicine & Toxicology · doi:10.37506/ijfmt.v14i4.12314
Jak postupovat v boji s inzulinovou rezistencí u pacientů s DM 2. typu
Haluzı́k, M. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.128
Metadata
- Authors
- Van Gaal, L., & Scheen, A.
- Affiliations
- Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium
- University of Liège (BE)
- ORCID
- Scheen, André
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-05-12
- Volume
- 38
- Issue
- 6
- Pages
- 1161-1172
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1893948433
- Cited by
- 221
- References
- 112
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 22 · 2023: 19 · 2022: 17 · 2021: 18 · 2020: 24 · 2019: 23 · 2018: 22 · 2017: 27 · 2016: 24 · 2015: 8
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, obesity, weight management, weight loss, pharmacotherapy, glucose-lowering medications, anti-obesity drugs, glycemic control, combination therapy, lifestyle intervention
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Therapy, Combination, Forecasting, Humans, Hypoglycemic Agents, Obesity, Weight Gain, Weight Loss, Anti-Obesity Agents, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.